Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$268.26 - $339.48 $113,742 - $143,939
424 Added 56.08%
1,180 $322,000
Q1 2024

May 13, 2024

SELL
$304.11 - $351.99 $18,550 - $21,471
-61 Reduced 7.47%
756 $261,000
Q4 2023

Feb 12, 2024

BUY
$269.37 - $365.04 $220,075 - $298,237
817 New
817 $264,000
Q2 2023

Aug 11, 2023

BUY
$359.49 - $486.4 $270,695 - $366,259
753 New
753 $285,000
Q2 2022

Aug 12, 2022

SELL
$463.67 - $597.16 $150,229 - $193,479
-324 Reduced 40.86%
469 $232,000
Q1 2022

May 13, 2022

SELL
$524.57 - $735.42 $120,126 - $168,411
-229 Reduced 22.41%
793 $447,000
Q4 2021

Feb 11, 2022

BUY
$708.84 - $794.68 $401,203 - $449,788
566 Added 124.12%
1,022 $772,000
Q3 2021

Nov 15, 2021

SELL
$657.71 - $825.77 $272,949 - $342,694
-415 Reduced 47.65%
456 $340,000
Q2 2021

Aug 13, 2021

BUY
$576.64 - $649.04 $81,882 - $92,163
142 Added 19.48%
871 $561,000
Q1 2021

May 14, 2021

BUY
$547.01 - $662.35 $31,179 - $37,753
57 Added 8.48%
729 $416,000
Q4 2020

Feb 12, 2021

SELL
$510.68 - $643.45 $45,450 - $57,267
-89 Reduced 11.7%
672 $392,000
Q3 2020

Nov 13, 2020

BUY
$454.43 - $535.6 $345,821 - $407,591
761 New
761 $392,000

Others Institutions Holding BIO

About BIO-RAD LABORATORIES, INC.


  • Ticker BIO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 24,633,900
  • Market Cap $7.89B
  • Description
  • Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, an...
More about BIO
Track Nat Simons's Portfolio

Track Nat Simons Portfolio

Follow Nat Simons (Meritage Group LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meritage Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Meritage Group LP and Nat Simons with notifications on news.